---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-057139"
form_type: "8-K"
ticker: "OCUL"
cik: "0001393434"
company_name: "OCULAR THERAPEUTIX, INC"
filed_at: "2023-05-08T23:59:59+00:00"
generated_at: "2026-06-15T12:34:35.300371+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Ocular Therapeutix Q1 net loss widens to $30.3M; DEXTENZA rev up 6% to $13.2M

## Summary
- Net loss of $30.3M ($0.39/share) vs $12.5M ($0.16/share) in Q1 2022; includes $6.6M non-cash derivative fair value charge.
- DEXTENZA net product revenue $13.2M (+6% YoY); total net revenue $13.4M. FY2023 revenue guidance reiterated at $55-60M.
- Cash & equivalents $79.0M at Mar 31, 2023 (down from $102.3M); cash runway to mid-2024 excluding planned OTX-TKI trials.
- OTX-TKI wet AMD Phase 1 12-month data to be presented June 2023; potentially start pivotal trial in Q3 2023.
- OTX-TIC glaucoma Phase 2 enrolling; top-line data expected Q4 2023.

## SEC filing metadata
- accession: 0001104659-23-057139
- form_type: 8-K
- ticker: OCUL
- cik: 0001393434
- company_name: OCULAR THERAPEUTIX, INC
- filed_at: 2023-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1393434/000110465923057139/0001104659-23-057139-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1393434/000110465923057139/tm2314977d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-057139
- JSON: https://secwatch.observer/filing/0001104659-23-057139.json
- Plain text: https://secwatch.observer/filing/0001104659-23-057139.txt

## Key facts
- Earnings Releases
  OCULAR THERAPEUTIX, INC reported the first quarter ended March 31, 2023 results: revenue $13.2 million. Guidance reaffirmed.
  - Period: the first quarter ended March 31, 2023
  - Revenue: $13.2 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: Net product revenue of DEXTENZA for the first quarter of 2023 was $13.2 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1393434/000110465923057139/0001104659-23-057139-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.